Please contact our sales representative to learn more information about this reagents.
Background
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, [1] and is designed for the treatment of asthma and other inflammatory diseases.[2] Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354[3] and taken through pre-clinical and early clinical development.